Pulmonary hypertension in Takayasu arteritis. (26th August 2018)

• Record Type: Journal Article
• Authors: Sari, Alper; Sener, Yusuf Z.; Firat, Esra; Armagan, Berkan; Erden, Abdulsamet; Oksul, Metin; Hekimsoy, Vedat; Asil, Serkan; Kilic, Levent; Kiraz, Sedat; Kaya, Ergun B.; Tokgozoglu, Lale; Akdogan, Ali
• Is Part Of: International journal of rheumatic diseases. Volume 21:Number 8(2018)
• Page Start: 1634
• Page End: 1639
• Publication Date: 2018-08-26
• Subjects: large vessel vasculitis -- pulmonary hypertension -- Takayasu arteritis; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.13354
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Aim: To determine the frequency and define the causes of pulmonary hypertension (PH) in patients with Takayasu arteritis (TA). Method: Sixty‐four TA patients were evaluated by transthoracic echocardiography (TTE). Having an estimated systolic pulmonary arterial pressure (sPAP) ≥40 mm Hg by echocardiography or if performed, mean PAP ≥25 mm Hg in right heart catheterization was defined as PH. Clinical, imaging and laboratory results of the TA patients were obtained from hospital files. Result: In total, seven (10.9%) patients had PH. Four patients had PH due to left‐sided heart disease (group 2 PH), three patients due to pulmonary arterial involvement (PAI; group 4 PH) and one patient due to atrial septal defect (group 1 PH). In one patient, combination of PAI, aortic insufficiency and pulmonary venous return anomaly was present and he was considered to have both group 2 and group 4 PH. PAI was more frequent (42.9% vs 15.7%) in patients with PH but the difference was not statistically significant. The percentage of patients treated with cyclophosphamide and/or biologics was higher in the group with PH as compared to the group without PH ( P = 0.015). One patient with group 4 PH had been on pulmonary arterial hypertension (PAH)‐specific agents for 8 years. Conclusion: Pulmonary hypertension is not infrequent in TA patients and all the potential causes of PH should be carefully evaluated. Patients with severe or treatment‐resistant disease are prone to have PH. PAH‐specific agents may be effective in patients with group 4 PH.